Candesartan

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Diabetic Nephropathy

Conditions

Diabetic Nephropathy, Hypertension

Trial Timeline

Aug 1, 2002 → Sep 1, 2004

NCT ID

NCT00320970

About Candesartan

Candesartan is a pre-clinical stage product being developed by AstraZeneca for Diabetic Nephropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT00320970. Target conditions include Diabetic Nephropathy, Hypertension.

What happened to similar drugs?

20 of 20 similar drugs in Diabetic Nephropathy were approved

Approved (20) Terminated (3) Active (0)

✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved

✅Anplag(Sarpogrelate) + PlaceboYuhanApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅Duloxetine + Pregabalin + PlaceboShionogiApproved

✅duloxetine hydrochlorideEli LillyApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00430833	Phase 2	UNKNOWN	—	—	Hypertrophic Cardiomyopathy
NCT00679640	Pre-clinical	Completed	Jan 1, 2008	Jul 1, 2010	Heart Failure
NCT00320970	Pre-clinical	Completed	Aug 1, 2002	Sep 1, 2004	Diabetic Nephropathy
NCT00252694	Phase 3	Completed	Aug 1, 2001	Apr 1, 2008	Type 2 Diabetes
NCT00252720	Phase 3	Completed	Aug 1, 2001	Apr 1, 2008	Type 1 Diabetes
NCT00130975	Phase 3	Completed	Apr 1, 2001	Sep 1, 2005	Atrial Fibrillation
NCT00150631	Phase 3	UNKNOWN	Nov 1, 2000	Dec 1, 2014	Hypertension

Competing Products

20 competing products in Diabetic Nephropathy

See all competitors

Product	Company	Stage	Hype Score
IVT aflibercept + Sham SC + SC CLS-TA	Clearside Biomedical	Phase 2	25
CHF6467 active	Comac Medical	Phase 1/2	22
Ruboxistaurin mesylate	Eli Lilly	Phase 3	40
KVD001 Injection	KalVista Pharmaceuticals	Phase 2	29
KVD001 Injection	KalVista Pharmaceuticals	Phase 1	23
Baricitinib + Placebo	Eli Lilly	Phase 2	35
LY3857210 + Placebo	Eli Lilly	Phase 2	35
UBX1325	Unity Biotechnology	Phase 2	25
Aflibercept + foselutoclax	Unity Biotechnology	Phase 2	25
UBX1325	Unity Biotechnology	Phase 1	19
CT-P42 + Eylea	Celltrion	Phase 3	40
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	43
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	43
CS-3150 + placebo	Daiichi Sankyo	Phase 2	35
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	35
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	40
DS-5565 + placebo	Daiichi Sankyo	Phase 3	40
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	40
DS-5565	Daiichi Sankyo	Phase 3	40
Beraprost sodium	Astellas Pharma	Pre-clinical	22